A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Brian Yu, MD
- Phone Number: +86 400 828 3900
- Email: brian.yu@hengrui.com
Study Contact Backup
- Name: Junye Xiong, MD
- Phone Number: +86-0518-82342973
- Email: junye.xiong.jx9@hengrui.com
Study Locations
-
-
-
Sofia, Bulgaria
- Recruiting
- ARENSIA Exploratory Medicine at "MBAL Sveta Sofia"
-
Principal Investigator:
- Marchela Koleva, Dr.
-
Contact:
- Marchela Koleva, Dr.
-
Sofia, Bulgaria
- Not yet recruiting
- UMHAT "Sv. Ivan Rilski", EAD
-
Contact:
- Robev Bozhil
-
Principal Investigator:
- Robev Bozhil
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 000000
- Not yet recruiting
- Hong Kong United Oncology Centre
-
Contact:
- Yu Chung Li
-
Principal Investigator:
- Yu Chung Li
-
Hong Kong, Hong Kong, China, 000000
- Not yet recruiting
- The Chinese University of Hong Kong
-
Contact:
- Herbert Long
-
Principal Investigator:
- Herbert Long
-
Hong Kong, Hong Kong, China, 000000
- Not yet recruiting
- The University of Hong Kong
-
Principal Investigator:
- Rina Hui
-
Contact:
- Rina Hui
-
-
-
-
-
Clémont, France
- Recruiting
- Gustave Roussy Cancer Campus
-
Contact:
- Florian Scotté
-
Principal Investigator:
- Florian Scotté
-
Lyon, France
- Not yet recruiting
- Centre Hospitalier Lyon Sud
-
Contact:
- Freyer Gilles
-
Principal Investigator:
- Freyer Gilles
-
Paris, France
- Not yet recruiting
- Groupe Hospitalier Pitie-Salpetriere
-
Contact:
- Abbar Baptiste
-
Principal Investigator:
- Abbar Baptiste
-
-
-
-
-
Bari, Italy
- Not yet recruiting
- Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
-
Contact:
- Guida Michele
-
Principal Investigator:
- Guida Michele
-
Milan, Italy
- Not yet recruiting
- Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)
-
Contact:
- Sartore-Bianchi Andrea
-
Principal Investigator:
- Sartore-Bianchi Andrea
-
Milan, Italy
- Not yet recruiting
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Contact:
- Antonuzzo Andrea
-
Principal Investigator:
- Antonuzzo Andrea
-
Pavia, Italy
- Not yet recruiting
- Fondazione IRCCS Policlinico San Matteo
-
Contact:
- Secondino Simona
-
Principal Investigator:
- Secondino Simona
-
-
-
-
-
Brzozów, Poland
- Not yet recruiting
- Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza
-
Principal Investigator:
- Joanna Kiszka
-
Contact:
- Joanna Kiszka
-
Poznan, Poland
- Not yet recruiting
- Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii
-
Contact:
- Rodryg Ramlau
-
Principal Investigator:
- Rodryg Ramlau
-
-
-
-
-
Bucharest, Romania
- Recruiting
- Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine
-
Principal Investigator:
- Laurentia Nicoleta Gales
-
Contact:
- Laurentia Nicoleta Gales
-
Cluj-Napoca, Romania
- Recruiting
- Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine
-
Principal Investigator:
- Tudor Eliade Ciuleanu
-
Contact:
- Tudor Eliade Ciuleanu
-
Craiova, Romania
- Not yet recruiting
- Centrul de Oncologie Sfantul Nectarie Craiova
-
Principal Investigator:
- Michael Schenker
-
Contact:
- Michael Schenker
-
-
-
-
-
Seoul, South Korea, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Do-Youn Oh
-
Principal Investigator:
- Do-Youn Oh
-
Seoul, South Korea, 05505
- Not yet recruiting
- Asan Medical Center
-
Contact:
- Kyu-pyo Kim
-
Principal Investigator:
- Kyu-pyo Kim
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, South Korea, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
Principal Investigator:
- Eun Hee Jung
-
Contact:
- Eun Hee Jung
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Pratia ES Sirius Barcelona
-
Principal Investigator:
- Santiago Viteri Ramirez
-
Contact:
- Santiago Viteri Ramirez
-
Córdoba, Spain
- Not yet recruiting
- Hospital Universitario Reina Sofía Córdoba
-
Contact:
- Elisabeth Inga Saavedra
-
Principal Investigator:
- Elisabeth Inga Saavedra
-
Lleida, Spain
- Not yet recruiting
- Hospital Universitari Arnau de Vilanova
-
Contact:
- Salud Salvia Antonieta
-
Principal Investigator:
- Salud Salvia Antonieta
-
Madrid, Spain
- Not yet recruiting
- Hospital Universitario HM Madrid Sanchinarro
-
Contact:
- Huertas Mondejar Helena
-
Principal Investigator:
- Huertas Mondejar Helena
-
Madrid, Spain
- Not yet recruiting
- Hospital Universitario Ramón y Cajal
-
Contact:
- Belén de Frutos González
-
Principal Investigator:
- Belén de Frutos González
-
Madrid, Spain
- Recruiting
- Pratia ES Hospital Universitario de Torrejon
-
Contact:
- Sara Custodio Cabello
-
Principal Investigator:
- Sara Custodio Cabello
-
Ourense, Spain
- Not yet recruiting
- Complejo Hospitalario Universitario de Orense
-
Contact:
- Salgado Fernandez Mercedes
-
Principal Investigator:
- Salgado Fernandez Mercedes
-
Sant Cugat del Vallès, Spain
- Not yet recruiting
- Hospital Universitario General de Cataluña
-
Contact:
- Xabier González Farré
-
Principal Investigator:
- Xabier González Farré
-
-
-
-
-
Izmir, Turkey (Türkiye)
- Not yet recruiting
- I.E.U. Medicalpoint Izmir Hospital
-
Principal Investigator:
- Cagatay Arslan
-
Contact:
- Cagatay Arslan
-
Kınıklı, Turkey (Türkiye)
- Not yet recruiting
- Pamukkale University Hospital
-
Principal Investigator:
- Yuksel Urun
-
Contact:
- Yuksel Urun
-
Sakarya, Turkey (Türkiye)
- Not yet recruiting
- Sakarya Univ. Training & Research Hosp. Oncology
-
Principal Investigator:
- Ilhan Hacibekiroglu
-
Contact:
- Ilhan Hacibekiroglu
-
Yenimahalle, Turkey (Türkiye)
- Not yet recruiting
- Ankara Oncology TRH Clinical Research Center
-
Contact:
- Ayse Ocak Duran
-
Principal Investigator:
- Ayse Ocak Duran
-
-
Ankara
-
Mamak, Ankara, Turkey (Türkiye)
- Not yet recruiting
- Ankara Univ Cebeci Hospital Medical Oncology
-
Principal Investigator:
- Yuksel Urun
-
Contact:
- Yuksel Urun
-
-
Istanbul
-
Fatih, Istanbul, Turkey (Türkiye)
- Not yet recruiting
- Istanbul Univ. Cerrahpasa Medical Faculty Hosp.
-
Principal Investigator:
- Mustafa Ozguroglu
-
Contact:
- Mustafa Ozguroglu
-
Kadıköy, Istanbul, Turkey (Türkiye)
- Not yet recruiting
- Goztepe Prof. Dr. Suleyman Yalcin City Hospital
-
Contact:
- Mahmut Gümüş
-
Principal Investigator:
- Mahmut Gümüş
-
Pendik, Istanbul, Turkey (Türkiye)
- Not yet recruiting
- Marmara University Pendik Training and Research Hospital
-
Contact:
- Osman Kostek
-
Principal Investigator:
- Osman Kostek
-
-
-
-
-
Kyiv, Ukraine
- Recruiting
- ARENSIA Exploratory Medicine LLC
-
Contact:
- Myroslava Doronina
-
Principal Investigator:
- Myroslava Doronina
-
-
-
-
California
-
Long Beach, California, United States, 90805
- Not yet recruiting
- Starling Oncology
-
Contact:
- Omkar Marathe
-
Principal Investigator:
- Omkar Marathe
-
Los Alamitos, California, United States, 90254
- Recruiting
- Cancer and Blood Specialty Clinic
-
Principal Investigator:
- Arati Chand
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA
-
Contact:
- Wanxing Chai-Ho
-
Principal Investigator:
- Wanxing Chai-Ho
-
-
Florida
-
Clermont, Florida, United States, 34711
- Recruiting
- Clermont Oncology Center
-
Contact:
- Gopal Kunta
-
Principal Investigator:
- Kunta Kunta
-
Coral Springs, Florida, United States, 33065
- Recruiting
- Oncology & Hematology Associates of West Broward
-
Principal Investigator:
- Sumit Sawhney
-
Miami, Florida, United States, 33141
- Not yet recruiting
- Starling Oncology / Oncology Institute of Hope & Innovation
-
Contact:
- David Luis Sumoza
-
Principal Investigator:
- David Luis Sumoza
-
Orange City, Florida, United States, 32763
- Recruiting
- Mid-Florida Hematology & Oncology Centers, P.A.
-
Contact:
- Santosh Nair
-
Principal Investigator:
- Santosh Nair
-
-
Illinois
-
Springfield, Illinois, United States, 62702
- Recruiting
- Springfield Clinic
-
Principal Investigator:
- Preet Singh
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Contact:
- Naomi Fei
-
Principal Investigator:
- Naomi Fei
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Not yet recruiting
- Hattiesburg Clinic Hematology/Oncology
-
Principal Investigator:
- John Hrom
-
Contact:
- John Hrom
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68516
- Recruiting
- Cancer Partners of Nebraska
-
Contact:
- Irfan Vaziri
-
Principal Investigator:
- Irfan Vaziri
-
-
New Jersey
-
Morristown, New Jersey, United States, 07039
- Not yet recruiting
- Morristown Medical Center
-
Principal Investigator:
- Se young Han
-
-
New York
-
New York, New York, United States, 10065
- Not yet recruiting
- MSK Cancer Center
-
Contact:
- Jodi Mones
-
Principal Investigator:
- Jodi Mones
-
Shirley, New York, United States, 11967
- Not yet recruiting
- New York Cancer and Blood Specialists One Oncology
-
Principal Investigator:
- Richard Zuniga
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years at screening.
- Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma [NSCLC], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer).
- Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 14- or 21-day treatment cycles.
- Platelet count < 85 x 109/L at enrollment.
- For Part B, experiencing a chemotherapy delay of ≥ 7 days due to CIT.
- At least 2 scheduled chemotherapy cycles of the same treatment regimen as was used prior to enrollment.
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
- Life expectancy ≥6 months.
- Signed ICF for voluntary participation in the study and good compliance.
Exclusion Criteria:
- WHO Grade ≥ 2 bleeding within 14 days prior to screening.
- Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).
- Hematologic malignancies.
- Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.
- Untreated brain metastases; or with leptomeningeal metastasis.
- Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).
- Severe cardiovascular disorders or interventions within 6 months.
- Have arterial/venous thrombosis with anticoagulation not tolerated for at least 6 weeks.
- Known bleeding disorders, platelet dysfunction.
- Severe haemorrhage during screening (e.g., gastrointestinal or intracranial hemorrhage) within 28 days prior to enrolment.
- Previous treatment with thrombopoietin receptor agonists (TPO-RAs) within 14 days prior to enrolment.
- Platelet transfusion within 72 hours prior to enrollment.
- Acute or uncontrolled hepatitis B&C infection.
- Human immunodeficiency virus (HIV) infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: Hetrombopag Olamine
|
For Part A, all participants would receive hetrombopag treatment. |
|
Experimental: Part B: Hetrombopag Olamine vs Hetrombopag Olamine Placebo
|
For Part B, participants would be randomized to receive hetrombopag treatment or matching placebo, respectively. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.
Time Frame: around 6 months.
|
around 6 months.
|
|
Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.
Time Frame: around 6 months.
|
around 6 months.
|
|
Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.
Time Frame: around 6 months.
|
around 6 months.
|
|
Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Adverse Events/Serious Adverse Events, safety lab parameters, vital signs, etc within study period, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Proportion of participants achieving platelet count ≥100×109/L without the use of rescue therapy within 14 days after initiating the investigational product treatment, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Platelet count nadir from Cycle 1 Day 1 until the primary treatment period, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Proportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
|
Proportion of participants with neutropenia during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.
Time Frame: around 3 years.
|
around 3 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SHR8735-303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.